Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.62 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.78 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.78 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.78 |
| ▸ | LTA4H | P09960 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL228398 | 1.00 | PSMB1 (0.78) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL1027972 | 0.98 | PSMB1 (0.80) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL2741667 | 0.98 | PSMB1 (0.80) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL227699 | 0.98 | PSMB1 (0.75) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL6442924 | 0.97 | PSMB1 (0.77) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL7626127 | 0.96 | PSMB1 (0.72) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL2344523 | 0.94 | PSMB1 (0.74) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL7132076 | 0.93 | PSMB1 (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL7139772 | 0.93 | PSMB1 (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| Hydrochloric Acid SCHEMBL4224584 | 0.93 | KDM4E (0.73) | PSMB1PSMB5PSMB2KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011029088-A2 | PREPARATION OF RALOXIFENE AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-03-10 | — | — | WO | claimed |
| WO-2005003116-A9 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-09-25 | — | — | WO | claimed |
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | claimed |
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | ERREGIERRE S.P.A (IT) | 2007-05-03 | — | — | US | claimed |
| EP-1641773-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.p.A. (IT) | 2006-04-05 | — | — | EP | claimed |
| WO-2005003116-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.P.A. (IT) | 2005-01-13 | — | — | WO | claimed |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2022226133-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-09-03 | — | — | US | disclosed |
| WO-2015156428-A1 | NOVEL METHOD FOR PREPARING AMORPHOUS RALOXIFENE HYDROCHLORIDE SALT AND NOVEL INTERMEDIATE USED THEREFOR | 코오롱생명과학 주식회사 | 2015-10-15 | — | — | WO | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| WO-1996040677-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040691-A1 | VINYL SULFOXIDES AND A PROCESS FOR THEIR SYNTHESIS | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5514826-A | INTERMEDIATES FOR 2-ARYLBENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5512701-A | REACTING SULFOXIDE DERIVATIVE WITH A SILYATING AGENT TO FORM SULFENATE SILYL ESTER, OPTIONALLY REACTING INTERMEDIATE WITH AN AMINE AND/OR A MERCAPTAN | ELI LILLY AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1996009045-A1 | ANTIESTROGENIC BENZOTHIOPHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0699672-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceutical agents | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | KAT2A, ADH1A, KAT2B | HRH3 83/4885PSMB1 682/4885PSMB5 898/4885 |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | SUMO2, SUMO1, SUMO3 | HRH3 1146/4885PSMB1 50/4885PSMB5 74/4885 |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | HRH3 3168/4885PSMB1 3699/4885PSMB5 3347/4885 |
| US-20200277271-A1 | SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF | SUMO2, SUMO1, SUMO3 | HRH3 1146/4885PSMB1 50/4885PSMB5 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.